Purdue’s donation will accelerate the creation of a generic naloxone spray by about a year. Harm Reduction Therapeutics hopes to launch the drug within the next two years. Purdue will not receive any revenue or royalties from the drug.
Michael Hufford, CEO of Harm Reduction Therapeutics, told Bloomberg the product will cost “a fraction” of the $125 price for a two-pack of Narcan.
“As the opioid epidemic has unfolded, the price of naloxone, despite it being a generic drug, has continued to go up,” Mr. Hufford said. “There has to be another way.”
Harm Reduction Therapeutics is petitioning U.S. regulators to have the drug sold over-the-counter at pharmacies. At present, about 45 states allow pharmacies to dispense the drug without a prescription.
More articles on opioids:
Cities pushing for safe injection sites face federal pushback
4 things to know about the Senate opioid bill
Drug companies race to make opioid alternatives: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
